Dapivirine (DPV) has been added as an HIV drug in the NNRTI class. Interactions with dapivirine are available on the website checker and iChart app and will soon be added to the PDF tables of interactions. A pharmacokinetic fact sheet for dapivirine is also available in the Prescribing Resources section of the website.
Dapivirine is administered as a vaginal ring and is used to reduce the risk of HIV-1 infection in combination with safer sex practices when oral pre-exposure prophylaxis (PrEP) is not used, cannot be used or is not available. Placed in the vagina, the ring slowly releases the antiretroviral medicine dapivirine over a period of 28 days.
Although dapivirine is metabolised by CYP450 and UGT enzymes, due to the low systemic exposure to dapivirine in women using the dapivirine vaginal ring, the risk of systemic drug-drug interactions is considered low.
